Ovid Therapeutics Inc. (NASDAQ:OVID) announced that the European Commission (EC) has granted orphan drug designation (ODD) to OV101 (gaboxadol) for the treatment of Angelman syndrome based on the results of the Phase 2 STARS trial. OV101 is believed to be the only delta (δ)-selective GABAA receptor agonist in clinical development for the treatment of certain neurodevelopmental disorders, including Angelman syndrome.
The
insider ownership percentage is the key indicator, can be used by investors, to
measure the outlook of senior management has on their company. Insider
ownership for the OVID is 12.10%. Institutional ownership refers to the
ownership stake in a company that is held by large financial organizations,
pension funds or endowments. The Institutional ownership for the OVID is
31.80%.
Insider trading is the buying or selling of any publicly traded company’s stock
and this can be done by someone who has non-public, material information about
that OVID. Insider trading can be illegal or legal depending on when the
insider makes the trade. It is illegal when the material information is still
non-public.
Institutional ownership is the amount of a Ovid Therapeutics Inc.
(NASDAQ:OVID)’s available stock owned by mutual or pension funds, insurance
companies, investment firms, private foundations, endowments or other large
entities that actually manage the funds on the behalf of others, so its an
interesting element for the traders to note it, and the Institutional ownership
for the OVID is 79.82%.
a Healthcare sector firm, Ovid Therapeutics Inc. (NASDAQ:OVID) stock climbs
24.86% on Monday and when day-trade ended the stock finally concluded at $2.31
and number of shares that changed hands during the day are 1.27 Million. The
number of shares OVID stock currently held by all its shareholders are 38.49
and floated shares, the number of shares are available for trading in an open
market on last trading day are 18.48. The average volume of shares for 3 months
is 600.29 and OVID stock value has moved between $1.53 – 11.55 in last one
year.
The Ovid Therapeutics Inc. (NASDAQ:OVID)’s latest earnings date is 8/6/2019.
The Gross margin is the difference between the revenue and the cost of goods
sold (COGS), divided by revenue. In other words, Gross Margin is a percentage
value, while Gross Profit is a monetary value. The stock has gained -4.55% in
2019 to date.
[FINVIZ TICKER=OVID]
U.S.
traded shares of Ovid Therapeutics Inc. (NASDAQ:OVID)’s monthly stock
performance is 44.37%, the quarterly performance is 31.25%, the half year
performance is calculated as -7.23%. The yearly performance of OVID is -70.83%.
The higher the volatility, the riskier the security. For example, when the
stock market rises and falls more than one percent over a sustained period of
time, it is called a “volatile” market, if the stock price stays
relatively stable, the security has low volatility. The Ovid Therapeutics Inc.
(NASDAQ:OVID) weekly volatility is measured as 9.97% and monthly volatility
measured as 7.85%.
The price to book ratio is 1.22, price to cash per share ration is 1.49.
Analysts mean target price for Ovid Therapeutics Inc. (NASDAQ:OVID) is $13.40 while analysts mean recommendation is 1.60. The current share price indicates that stock is -79.83% away from its one year high and is moving 50.98% ahead of its 52-week low. OVID’s distance from 20 day simple moving average is 32.95% and distance from 50-Day simple moving average is 30.58%.